Related Experiment Video

Updated: Mar 9, 2026

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

2.3K

Rucaparib Approved for Ovarian Cancer

    Cancer Discovery
    |January 7, 2017
    PubMed

    Insights

    The FDA approved rucaparib, a PARP inhibitor, for advanced ovarian cancer patients with BRCA mutations. This approval targets women who have undergone prior chemotherapy, marking a significant advancement in targeted cancer therapy.

    Area of Science:

    • Oncology
    • Genetics
    • Pharmacology

    Background:

    • Advanced ovarian cancer often presents challenges in treatment, particularly after multiple chemotherapy regimens.
    • BRCA1 and BRCA2 gene mutations are key drivers in a subset of ovarian cancers, influencing therapeutic strategies.

    Purpose of the Study:

    • To announce the U.S. Food and Drug Administration (FDA) approval of a new therapeutic agent for a specific patient population.
    • To highlight the importance of companion diagnostics in personalized medicine.

    Main Methods:

    • The FDA reviewed clinical data on the efficacy and safety of rucaparib.
    • The FoundationFocus CDxBRCA test was evaluated for its ability to accurately detect BRCA alterations.

    Main Results:

    • Rucaparib (PARP inhibitor) received FDA approval for treating advanced ovarian cancer.
    • The FoundationFocus CDxBRCA test was approved as a companion diagnostic for identifying eligible patients.

    Conclusions:

    • The approval of rucaparib offers a new targeted treatment option for women with advanced ovarian cancer and BRCA mutations.
    • Companion diagnostics are crucial for ensuring appropriate patient selection for targeted therapies like rucaparib.

    More Related Videos

    Evaluating In Vitro DNA Damage Using Comet Assay10:43

    Evaluating In Vitro DNA Damage Using Comet Assay

    Published on: October 11, 2017

    40.0K
    Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

    Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

    Published on: August 12, 2015

    9.7K

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.9K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.0K
    Cancer-Critical Genes II: Tumor Suppressor Genes01:05

    Cancer-Critical Genes II: Tumor Suppressor Genes

    Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
    When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
    Such genes that act...
    10.0K
    Cancer Therapies02:49

    Cancer Therapies

    Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
    However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
    10.5K
    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    6.1K